Why Do Dogs Leave Probiotic Trials Early?

Dylan in Lowell started tracking Grady’s stools on the fridge calendar after the 5-year-old neutered hound mix joined a 28-day feeding trial for diarrhea. By day 9 the stools looked firmer, by day 12 Grady vomited twice and refused the chew, and by day 14 Dylan withdrew him because the protocol did not allow a diet change.

That withdrawal is not a footnote. In a small trial, every dog that leaves shifts the average.

The surprising limitation is this: a finished chart can look clean while the dogs that struggled have disappeared from the math. My position is direct — trace the stress and metabolic axis before you trust a stool claim, then read the dropout table before you read the conclusion. Supplements should be described only as supporting normal function, and normal function includes appetite, cortisol feedback, and gut motility under stress.

Vets often see the same pattern outside trials. A dog with loose stool, a new supplement, a car ride, a boarding stay, and a cortisol surge can look like non-response when the axis is driving the sign. That does not excuse a weak product, but it explains why careful trials lose dogs for reasons that have little to do with the capsule.

What a dropout actually removes

Dogs leave trials for ordinary reasons: vomiting, worsening diarrhea, owner noncompliance, a concurrent illness, a forbidden food or antibiotic, a move, or simply a dog that will not eat the test chew. Each exit removes both an outcome and a microbiome trajectory.

When exits cluster in one group, the groups are no longer comparable. If more gassy or nauseated dogs quit the probiotic arm, the remaining probiotic group looks healthier by selection, not by effect.

The CONSORT 2010 statement in the BMJ exists for this reason. It asks authors to report how many participants were randomized, how many completed each arm, and why each one left. A dog trial that skips that flow diagram deserves skepticism.

Myth versus reality on missing dogs

Myth: dropouts mean the probiotic failed or harmed those dogs.

Reality: some dropouts reflect intolerance, some reflect improvement, and some reflect life. An owner whose dog normalizes quickly may stop showing up for rechecks. An owner whose dog needs pancreatic enzymes, a diet change, or cobalamin support may leave to get standard care.

Myth: you can ignore a 10% loss in a 30-dog trial.

Reality: you cannot. In a trial with 15 dogs per arm, three related withdrawals can erase or create a “significant” stool difference. Small canine nutrition trials have little buffer.

That buffer matters because response is uneven even among finishers. In the recent canine diarrhea pilot published in Frontiers in Veterinary Science, the authors reported that “Diversity metrics did not distinguish non-responders from responders.” The paper is titled Pilot study evaluating tolerability and changes in fecal microbiota associated with novel probiotic administration to dogs with diarrhea (2026).

That single line should temper label hype.

If laboratory diversity cannot separate responders after completion, losing several borderline dogs to follow-up makes separation even harder to trust.

A practical sequence before you believe a claim

Follow this order the next time a brand cites “clinically studied” or “trial proven.”

Check the starting count and the finishing count by group. Look for the CONSORT-style flow chart or a plain table with reasons: adverse event, lack of efficacy, owner withdrawal, protocol violation, lost to follow-up.

Ask whether analysis kept every randomized dog. Intention-to-treat or a stated imputation method preserves the randomization. A per-protocol-only result tells you what happened in the dogs that could tolerate and finish the product, which is useful but narrower.

Look for differential loss. Two exits for vomiting in the treatment arm versus none in placebo is a signal, even when the final p-value looks favorable. So is higher owner withdrawal in the placebo arm, which can inflate apparent benefit.

Trace the axis before the recommendation. Was stress, estrus, diet change, boarding, antibiotics, or an endocrine or pancreatic disorder screened or tracked? A dog with unrecognized exocrine pancreatic insufficiency, hypercortisolism, or hypothyroid-related motility change supports normal function differently than a healthy dog with diet-related soft stool. For context on whole-patient signs, compare Signs Your Dog Needs a Probiotic: A Vet’s Whole-Patient Guide and How to Tell if a Probiotic Is Working for Your Dog’s Stool.

Then judge stool the way trials should: same diet, same scoring scale, same recheck window. A useful primer is Bovine Colostrum for Dogs With Diarrhea: What It Can and Can’t Do, which separates supportive care from disease treatment without overstating either.

Reject any claim built on finishers alone when the dropout reasons point one way.

Dylan made the right call by leaving rather than forcing Grady through vomiting to protect a dataset. A good investigator would record that exit, keep Dylan’s early stool scores in the analysis, and disclose the refusal in the results.

Use that standard as your filter, and most “90% improved” banners shrink to what they are: a small, leaky trial supporting normal digestive function in the dogs that stayed, not proof for every dog that tries the jar.